Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical …